GSK bets big on China, expanding recruitment and broadening investment strategy to include TCM

GlaxoSmithKline (GSK) is no stranger to China. The company is one of the early foreign corporations to make heavy investments and R&D bets in China, with pharmaceutical research and clinical trials costs ramping  to a speculative figure of more than RMB 1 billion to date. Since 2008, China has been ...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email Thank you!

Related Research

BioNTech to set up its regional headquarters and an mRNA vaccine manufacturing facility in Singapore

News Commentary | May 12, 2021

Pfizer's biotech partner that developed the mRNA vaccine against COVID‑19 has moved quickly to ensure it can be elastic in its response to shifting regional and global supply needs for its vaccine given the unpredictable outbreaks in recent times. This move also comes just weeks after Sanofi ... To read more, click here.

Singaporean precision medicine startup Hummingbird Bioscience nets $125 million in Series C funding led by Novo Holdings

News Commentary | May 24, 2021

This will further expand Hummingbird's proprietary Rational Antibody Discovery (RAD) platform for novel therapeutic monoclonal antibodies. The market for therapeutic antibodies is rapidly growing, as new drugs have been approved for treating various human diseases, including many cancers and ... Not part of subscription

Lymphoma patients in Australia can now access CAR T cell therapy

News Commentary | August 06, 2021

The Australian government will now fund the use of Yescarta, a CAR T cell therapy from Gilead/Kite Pharma for the treatment of certain aggressive lymphomas. Yescarta is only the second CAR T cell therapy to have been approved by the FDA after Novartis' Kymriah, as we discuss in our recent insight on... Not part of subscription